eligibility_summary
Eligible: Adults ≥18 with untreated aggressive B‑cell lymphoma (HGBCL double/triple‑hit or NOS, PMBCL, BL, DLBCL‑MYC, CD19+ PBL), ECOG 0–3, ANC ≥1k, Plt ≥50k (unless marrow), AST/ALT/GGT ≤3×ULN, bili <1.5×ULN, CrCl ≥30, LVEF ≥50%. CNS ok only in BL (not intraparenchymal), HIV+ on ART ok. Exclude: major effusions, hypersensitivity, HBV unless undetectable+prophylaxis, viremic HCV, active infection, QTc>480, other cancer ≤3y, serious cardio‑pulm disease, pregnancy/breastfeeding, Child‑Pugh C.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase 1 trial tests loncastuximab tesirine plus DA‑EPOCH‑R in previously untreated aggressive B‑cell lymphomas. Drugs/mechanisms: loncastuximab tesirine (ADCT‑402, antibody–drug conjugate) binds CD19 and delivers a pyrrolobenzodiazepine (PBD) dimer payload that crosslinks DNA, causing cell death, rituximab (anti‑CD20 monoclonal antibody) triggers ADCC/CDC and direct apoptosis, etoposide (topoisomerase II inhibitor), doxorubicin (anthracycline, DNA intercalation, topoisomerase II inhibition, ROS), cyclophosphamide (alkylating DNA crosslinker), vincristine (vinca alkaloid, microtubule polymerization inhibitor), prednisone (glucocorticoid, lympholytic). Targets/pathways: CD19+ and CD20+ malignant B cells, DNA integrity/replication and repair pathways, mitotic spindle function, and apoptosis signaling. Goal: define MTD/RP2D for efficacy against DLBCL/HGBCL/PMBCL/Burkitt/plasmablastic.